Preparation of 3,4-diaminopyridine microparticles by solvent-evaporation methods.

[1]  D. Sanders.  3,4‐Diaminopyridine (DAP) in the Treatment of Lambert‐Eaton Myasthenic Syndrome (LEMS) a , 1998, Annals of the New York Academy of Sciences.

[2]  J. Rothwell,et al.  An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. , 1998, Brain : a journal of neurology.

[3]  C. Bever,et al.  Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients , 1996, Neurology.

[4]  M. Aisen,et al.  A double-blind placebo-controlled study of 3,4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit , 1996, Journal of the Neurological Sciences.

[5]  D. Sevilla,et al.  3,4-Diaminopyridine as a treatment for amyotrophic lateral sclerosis , 1995, Journal of the Neurological Sciences.

[6]  C. Polman,et al.  4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. , 1994, Archives of neurology.

[7]  C. Bever,et al.  Preliminary trial of 3,4‐diaminopyridine in patients with multiple sclerosis , 1990, Annals of neurology.

[8]  J. Daube,et al.  3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. , 1989, The New England journal of medicine.

[9]  R. Bodmeier,et al.  Polylactic acid microspheres containing quinidine base and quinidine sulphate prepared by the solvent evaporation technique. I. Methods and morphology. , 1987, Journal of microencapsulation.

[10]  I. G. Marshall,et al.  The effects of 3,4-diaminopyridine on acetylcholine release at the frog neuromuscular junction. , 1980, European journal of pharmacology.

[11]  S. Thesleff,et al.  Aminopyridines and synaptic transmission , 1980, Neuroscience.

[12]  G. Hardee,et al.  Microencapsulation of antimicrobial ceftiofur drugs. , 1997, Pharmaceutical development and technology.

[13]  P. Maincent,et al.  Preparation and characterization of ethylcellulose microspheres containing 5-fluorouracil. , 1994, Journal of microencapsulation.

[14]  C. Bever.  The current status of studies of aminopyridines in patients with multiple sclerosis , 1994, Annals of neurology.

[15]  C. Bever,et al.  Analysis of 3,4-diaminopyridine in human serum by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. , 1989, Journal of chromatography.